Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
复制标题
DOI：
10.1016/s0090-4295(01)01405-4
复制
发表时间：
2001-12-01
期刊：
影响因子：
2.1
通讯作者：
Slawin, KM
中科院分区：
文献类型：
--
作者：
Shariat, SF;Andrews, B;Slawin, KM
目标。循环中白细胞介素6(IL-6)水平升高与癌症转移有关。IL-6与细胞膜或可溶性IL-6受体(IL-6sR)结合，诱导gp130同源二聚化，激活下游信号转导。我们验证了术前血浆IL-6和IL-6sR水平与前列腺癌的分期、进展和前列腺癌根治术后转移相关的假说。检测120例前列腺癌根治术患者、44例非前列腺癌患者、19例前列腺癌区域淋巴结转移患者和10例前列腺癌骨转移患者的血浆IL-6和IL-6sR水平。骨转移瘤患者血浆IL-6和IL-6sR水平最高(P
Objectives. Elevated circulating levels of interleukin 6 (IL-6) have been associated with cancer metastasis. IL-6 binds either to membrane or to soluble IL-6 receptor (IL-6sR), which then induces homodimerization of gp130 that activates downstream signaling. We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels are associated with prostate cancer stage, progression, and metastasis after radical prostatectomy.Methods. Plasma levels of IL-6 and IL-6sR were measured in 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer, 44 healthy men without any cancer, 19 men with prostate cancer metastatic to the regional lymph nodes, and 10 men with prostate cancer metastatic to bone.Results. Plasma IL-6 and IL-6sR levels were highest in patients with bone metastases (P